Nov 14, 2024 | Business, Chronic Disease, Diabetes, Disease Area Trends
For years, Eli Lilly’s main contributions to the Diabetes market were their insulins: fast-acting analog Humalog® and human insulin Humalin and two premix offerings in analog Humalog® Mix 50/50 and human premix Humalin 75/25. Despite a legacy category, this portfolio...
Nov 14, 2024 | Chronic Disease, Diabetes, Disease Area Trends
Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog® and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1...
Nov 14, 2024 | Case Study, Case Study Forecasting
The Children’s Hospital of Philadelphia–Policy Lab approached Ozmosi for help in supporting its application for federal funding to establish a new organizational structure to better support children in the Philadelphia foster care system. The proposed structure was...
Nov 14, 2024 | Case Study, Case Study Forecasting
The Asia-Pacific R&D unit of a large, multinational pharmaceutical company needed a pipeline prioritization approach to guide regional investment and development efforts to maximize continued growth. The portfolio team required a flexible approach that...
Nov 14, 2024 | Case Study, Case Study Forecasting, Case Study Portfolio
The oncology team of a major multinational pharmaceutical company asked Ozmosi to provide additional forecasting support for a newly acquired product. They needed to update and validate the current forecast models to identify the most effective development strategies...
